X4 Pharmaceuticals, Inc (XFOR): Capital Expenditures
$0
Year ended 2025-12-31
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | -100.0% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $326.0K | +443.3% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $60.0K | -41.7% | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | $103.0K | -83.3% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $615.0K | -54.8% | 2024-03-21, From 2021-01-01 |
| 2020-12-31 | $1.36M | +682.8% | 2023-03-21, From 2020-01-01 |
| 2019-12-31 | $174.0K | n/a | 2022-03-17, From 2019-01-01 |
| 2018-12-31 | $0 | -100.0% | 2021-03-19, From 2018-01-01 |
| 2017-12-31 | $378.0K | +417.8% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $73.0K | n/a | 2019-03-11, From 2016-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $0 | -100.0% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $607.0K | +237.2% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $85.0K | -66.0% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.45M | -88.7% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $102.0K | -61.8% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $2.60M | -26.3% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $607.0K | -93.1% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $133.0K | n/a |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $574.0K | -81.6% |
Compare XFOR, CCCC, DTIL, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗